Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Michael E. Hurwitz, Scott S. Tykodi et al.|Journal of Clinical Oncology|2021Cited by 81
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 studyAdi Diab, Michael E. Hurwitz, Scott S. Tykodi et al.|Regular and Young Investigator Award Abstracts|2020Cited by 7
Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.Reinhard Dummer, Georgina V. Long, Stéphane Dalle et al.|Journal of Clinical Oncology|2024Cited by 4